SOBI Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company is in strategic partnership with Innate Pharma SA to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Swedish Orphan Biovitrum (STO: SOBI)
›
Swedish Orphan Biovitrum (STO: SOBI) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 2,207 employees.
The shares were at 467.80 SEK on 19 November 2026, up 37.5% over 52 weeks. Its 52-week range is 314.40 SEK to 507.00 SEK: the price is 7.7% below the high and 48.8% above the low.
At a market capitalisation of 162.80B SEK, it trades at 24.7 times trailing earnings and 30.1 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 26.3, so SOBI is valued in line with them.
Swedish Orphan Biovitrum reports return on equity of 1.3%, an operating margin of 30.9% and revenue up 17.3% year over year.
Its debt exceeds its cash by 15.15B SEK, a debt-to-equity ratio of 0.30. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 12 analysts cover the stock, with an average rating of Buy; their mean price target of 506.50 SEK is 8.3% above the current price. The next earnings report is expected on 4 February 2027.